Tenax Therapeutics, Inc. (TENX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tenax Therapeutics, Inc. on June 30, 2026, reporting events occurring on June 29, 2026. The filing details the execution of a new Supply Agreement and an amendment to an existing License Agreement with Orion Corporation regarding the orally administered levosimendan product.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on contractual agreements rather than financial performance results.
Material Changes and Agreements
- Supply Agreement: Tenax and Orion entered into a Supply Agreement for the manufacture and supply of the Oral Product. The agreement covers forecasting, ordering, delivery, quality, pricing, and non-conforming product provisions. It includes cost-sharing for scaling manufacturing capabilities.
- Term and Termination: The Supply Agreement has an initial term of five years from the first delivery, with automatic three-year renewals unless 24 months' prior notice is given. Termination is permitted for material breach (with a 60-day cure period), insolvency, or termination of the underlying License Agreement.
- Sixth Amendment to License Agreement: Concurrently, the parties executed the Sixth Amendment to their 2013 License Agreement. This amendment extends the deadline for obtaining U.S. regulatory approval for the Product to December 31, 2035, to avoid termination rights based on failure to achieve this milestone.
- Additional Requirements: The amendment imposes new information and cybersecurity compliance requirements on Tenax.
Outlook, Risks, and Management Commentary
The filing indicates a strategic commitment to advancing the Oral Product through a formalized supply chain and an extended regulatory timeline. The extension of the approval deadline to 2035 suggests management anticipates a longer development or regulatory review process. The full text of the Supply Agreement is intended to be filed as an exhibit to the upcoming Form 10-Q.
Key Facts for Investor Verification
- Verify the specific cost-sharing terms for scaling Orion's manufacturing capabilities in the full Supply Agreement.
- Confirm the pricing structure and volume commitments within the Supply Agreement once filed in the Form 10-Q.
- Assess the impact of the extended regulatory deadline (December 31, 2035) on the company's cash burn rate and capital requirements.
- Review the specific cybersecurity and information requirements imposed by the Sixth Amendment.